The End of the GLP-1 Shortage — and What It Means
The FDA says the shortages of the blockbuster weight-loss drugs are over. That decision reshapes who can legally make them, where the telehealth market goes next, and what is actually known about the copies.
For roughly two years, the GLP-1 medications behind the weight-loss boom — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — were in such short supply that federal rules let pharmacies make their own copies. That era is ending. Across late 2024 and early 2025, the U.S. Food and Drug Administration declared both shortages resolved, starting a countdown that closes the door on mass-produced compounded versions and forces a fast-growing telehealth industry to change course.
What Actually Changed
Under U.S. law, compounding pharmacies may make copies of a brand-name drug mainly when that drug is officially in shortage. Once the FDA removes a drug from its shortage list, that permission largely goes away. That is exactly what happened here.
- TirzepatideThe FDA declared the shortage resolved in a declaratory order dated December 19, 2024. State-licensed 503A pharmacies had 60 days (until February 18, 2025) and larger 503B outsourcing facilities had 90 days (until March 19, 2025) to stop compounding.
- SemaglutideThe FDA marked this shortage "resolved" on February 21, 2025. 503A pharmacies had until April 22, 2025, and 503B facilities until May 22, 2025, to cease.
- After those dates, a pharmacy generally cannot make a product that is "essentially a copy" of the approved drug unless a prescriber documents a clinically significant difference for a specific patient.
This was not a clean, uncontested switch. The tirzepatide shortage was first declared over in October 2024; an industry group representing compounders sued, the FDA agreed to reconsider, and it re-confirmed the shortage was resolved in December. Compounders challenged the semaglutide decision too. In short, the "end" of the shortage has been legally contested rather than universally settled. (These dates are documented in the FDA's December 19, 2024 declaratory order and its compounding guidance, and are corroborated by independent legal and industry summaries.)
A Reckoning for Telehealth
The compounded market grew large during the shortage. One platform, Mochi Health, reported serving more than 10,000 patients on compounded semaglutide, and telehealth company Hims & Hers projected roughly $2.4 billion in revenue for 2025. (These figures come from trade press reporting company statements, not audited filings.) With mass compounding off the table, several companies are pivoting to 503A "personalized-dose" compounding — tailoring a formula to an individual patient — as a way to keep selling.
Once the FDA removes a drug from its shortage list, the legal basis for making copies of it largely disappears.
For patients, the practical effect is that the cheaper, widely marketed compounded versions are being pulled back. Whether personalized-dose compounding is a legitimate clinical route or a workaround will depend on how regulators interpret each case.
How the Approved Drugs Perform
The evidence behind the brand-name products is strong, and it comes from large randomized trials.
- STEP 1 (semaglutide 2.4 mg; 1,961 adults with overweight or obesity but not diabetes; 68 weeks with lifestyle changes): average weight change of -14.9% versus -2.4% on placebo, and 86.4% of people lost at least 5% of body weight versus 31.5% on placebo.
- SURMOUNT-1 (tirzepatide; 2,539 adults with obesity; 72 weeks)average weight change of -15.0%, -19.5%, and -20.9% at the 5-, 10-, and 15-mg doses versus -3.1% on placebo. A separate "up to 22.5%" figure that circulates reflects people who adhered closely to treatment; both estimates are legitimate, so it matters which one is being quoted.
- SELECT (semaglutide 2.4 mg; 17,604 adults with cardiovascular disease and overweight/obesity but not diabetes): major cardiac events occurred in 6.5% versus 8.0% on placebo — a hazard ratio of 0.80 — pointing to a heart benefit beyond weight loss.
- SURMOUNT-5 (the first published head-to-head trial; 751 adults; 72 weeks)tirzepatide outperformed semaglutide, -20.2% versus -13.7%.
These are averages, not promises. Results reflect specific doses, gradual dose increases, and accompanying lifestyle changes; individual outcomes vary widely. Gastrointestinal side effects such as nausea, diarrhea, and vomiting are common, and weight regain is common after stopping — something the STEP 1 extension documented. It is also worth knowing that these registrational trials were funded by the drugs' makers (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide), which is standard for such studies but worth disclosing.
The Copies: What We Don't Know
Here is a gap that is easy to miss. Every efficacy and heart-outcome trial above studied the branded, FDA-approved drug. There are no comparable randomized trials of compounded, grey-market, or so-called "research-use-only" or "research peptide" semaglutide or tirzepatide. Those products are not FDA-approved, and their potency, purity, sterility, and dosing are not evaluated by the FDA. The strong results from the brand-name trials should not be assumed to carry over to copies — the honest position is that their real-world effectiveness and safety simply have not been established the same way.
The FDA has also flagged a specific safety concern. In an alert from July 2024, it warned that compounded injectable semaglutide had been linked to dosing errors — some patients reportedly injected roughly ten times the intended dose after measuring it incorrectly — with reported adverse events including hospitalizations. That measurement risk was part of the safety rationale for restricting compounding once the shortage ended. (Aggregate tallies of reports or deaths that circulate in secondary coverage could not be confirmed from primary sources, so we do not repeat them here.)
What This Means If You're Taking One
If you have been getting a compounded GLP-1 through a telehealth service, the supply and the rules around it are shifting, and the version you receive may change. The approved drugs have robust evidence behind them; the copies do not have their own trials, and unapproved "research" products add real uncertainty about what is actually in the vial. Decisions about switching, continuing, or stopping — and about managing side effects or the risk of weight regain — are ones to work through with a licensed healthcare professional who knows your medical history.
- 01 American Med Spa Association — 'Tirzepatide Shortage Ends', 2025 americanmedspa.org ↗Regulatory summary of the December 19, 2024 tirzepatide declaratory order and the 60-/90-day compounding wind-down.
- 02 McDermott Will & Emery — 'Semaglutide Shortage Resolved', 2025 mcdermottlaw.com ↗Law-firm advisory on the February 21, 2025 semaglutide resolution and the 503A/503B cease-compounding dates.
- 03 Pharmaceutical Technology — 'The GLP-1 drug shortage is over. What's next for the compounders?', 2025 pharmaceutical-technology.com ↗Trade reporting on the compounded market, the 503A personalized-dose pivot, Mochi patient counts (more than 10,000), and the Hims & Hers $2.4bn revenue projection.
- 04 Partnership for Safe Medicines — 'July 29, 2024: FDA issued new alert about compounded semaglutide', 2024 safemedicines.org ↗Patient-safety nonprofit reporting the FDA alert on compounded-semaglutide dosing errors and hospitalizations.
- 05 AHRQ Patient Safety Network (PSNet) — FDA compounded semaglutide dosing-errors alert, 2024 psnet.ahrq.gov ↗U.S. government patient-safety database documenting reported measurement errors and adverse events.
- 06 Semaglutide 2.4 mg for obesity: -14.9% vs -2.4% weight change over 68 weeks (summarized by the American College of Gastroenterology).
- 07 SURMOUNT-1 trial (Jastreboff et al.), N Engl J Med, 2022 pubmed.ncbi.nlm.nih.gov ↗Tirzepatide for obesity: -15.0% to -20.9% weight change across doses over 72 weeks (PubMed abstract).
- 08 Semaglutide 2.4 mg cardiovascular outcomes: major events 6.5% vs 8.0%, hazard ratio 0.80 (American College of Cardiology summary).
- 09 SURMOUNT-5 trial, N Engl J Med, 2025 acc.org ↗First published head-to-head trial: tirzepatide -20.2% vs semaglutide -13.7% over 72 weeks (ACC journal scan).
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
